LUCIUS 卢修斯 波生坦 Bosentan肺动脉高压

波生坦

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Bosentan

老挝国家食药监局批准上市
老挝国家药检所检测认证

Compesition:

肺动脉高压

Each liim-coaled tablel contaias Bosentan
monohydrate 129.08 mg equivaicnt to

LUCiUS

Bocentn

PHARMACEUTICA

adication:
LuciBose is an endothelin receptor antagomast
ndiested for the treatment of palmonary arteria

ht duuns to improve exercise ability and to
decrease clinieal sareaninn

LuciBose

ients aged 3 years and older wit
ldiopathic or congenital PAH to imn

palmomary yasenAt te iproe

eroisace (PVR), whichis
gected to result in an imorovement in e

FDA批准

ability

Dosage and Use

Bosentan Tablets

Pahtents older than 12 vears of a
uai tice daily; for patients weighing
greater than 40 kg, increase to 125 mg orally twice

Rx Onl

orage: in a dry place and store at 20C fo 25C.

125mg

Keen medicine out of reach of Children. Do nol
oktister LactBose during Pregnancy and

PLFASF SFE PACKAGE INSER
Manufactured and Marketed by:

权威认证

LUCIUS

Thongmang village. Xaythany distriet.
Vientiane Capital, Laos
www.lucius.la
araing : fo be sold by retail on prescription
hycians only, and as directed

56 Tablets

口碑质量

适应症:

波生坦是一种内皮素受体拮抗剂,用于治疗肺动脉高压(PAH)(WHO第1
类):
· 适用于成人,改善运动能力并减缓临床恶化。
·适用于3岁及以上患有特发性或先天性PAH的儿童患者,改善肺血管阻

力(PVR),预计可改善运动能力。
推荐剂量:
· 12岁以上患者:起始剂量为62.5mg,每日两次;体重超过40kg的患者,4周
后增至125mg,每日两次。
· 12岁及以下患者:剂量根据体重而定(见详细说明书)。
,如果患者出现氨基转移酶升高超过正常上限(ULN)的3倍,则应降低剂量并
密切监测。